Related Experiment Video
Updated: Jul 16, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Plasma lipoprotein(a) indicates risk for 4 distinct forms of vascular disease
Gregory T Jones1, Andre M van Rij, Jennifer Cole
1Department of Medical and Surgical Sciences, University of Otago, Dunedin, New Zealand. greg.jones@otago.ac.nz
Insights
Elevated lipoprotein(a) [Lp(a)] is a significant risk factor for coronary artery disease and other vascular conditions. This study confirms Lp(a) poses a similar risk across four major vascular diseases, independent of other factors.
Area of Science:
- Cardiovascular Medicine
- Clinical Chemistry
- Genetics and Genomics
Background:
- Elevated lipoprotein(a) [Lp(a)] is a known predictor of coronary artery disease (CAD).
- The comparative risk of Lp(a) for other vascular diseases versus CAD has not been extensively studied in a single population.
- This research investigates the association between Lp(a) and four distinct vascular diseases.
Purpose of the Study:
- To determine the risk association of elevated lipoprotein(a) [Lp(a)] with coronary artery disease (CAD), peripheral vascular disease (PVD), ischemic stroke, and abdominal aortic aneurysm (AAA).
- To compare the magnitude of risk conferred by Lp(a) across these four vascular conditions within a single study cohort.
- To assess whether the Lp(a) risk association is influenced by confounding factors and lipid-lowering therapies.
Main Methods:
- Plasma Lp(a) levels were measured using an Lp(a) ELISA in 384 CAD patients, 262 PVD patients, 184 ischemic stroke patients, 425 AAA patients, and 230 disease-free controls.
- Association studies were conducted using logistic regression, adjusting for age, sex, diabetes, plasma lipids, and medical history (hypertension, hypercholesterolemia, smoking).
- A clinical cutoff for Lp(a) was set at >45 nmol/L, representing the 75th percentile in controls.
Main Results:
- Increased Lp(a) concentrations (>45 nmol/L) were identified as a significant risk factor for all four vascular disease groups studied.
- Adjusted odds ratios for Lp(a) as a risk factor ranged from 1.96 for CAD to 2.33 for PVD.
- The risk associated with Lp(a) was consistent across all disease groups and independent of confounders, including statin/fibrate therapy.
Conclusions:
- Lipoprotein(a) [Lp(a)] is a stable risk factor of comparable magnitude for four major vascular diseases: CAD, PVD, ischemic stroke, and AAA.
- The identified association between elevated Lp(a) and vascular disease risk was not modified by exposure to standard lipid-lowering treatments.
- These findings underscore the importance of Lp(a) as a universal marker for vascular risk assessment.
Background:
Increased lipoprotein(a) [Lp(a)] concentrations are predictive for coronary artery disease (CAD). The risk conferred by Lp(a) for other types of vascular disease compared with CAD has not been investigated within a single population. This study aimed to investigate Lp(a) risk association for 4 different types of vascular disease (including CAD) within a predominantly white population.
Methods:
We used an Lp(a) ELISA that measures Lp(a) independently of apolipoprotein(a) size to measure plasma Lp(a) in patients [384 CAD, 262 peripheral vascular disease, 184 ischemic stroke (stroke), 425 abdominal aortic aneurysm] and 230 disease-free controls. We then conducted association studies with logistic regression, integrating the potential confounding effects of age, sex, diabetes, plasma lipids, and a history of previous hypertension, hypercholesterolemia, and smoking.
Results:
Multivariate analyses with Lp(a) concentrations of >45 nmol/L (the 75th percentile value for controls) as the clinical cutoff showed increased Lp(a) concentrations to be a risk factor for all disease groups, with adjusted odds ratios ranging from 1.96 [95% confidence interval (CI) 1.24-3.08] for CAD to 2.33 (95% CI 1.39-3.89) for PVD. The risk conferred by Lp(a) appeared to be independent of other confounders, including exposure to statin/fibrate therapies. Similar odds ratios and CIs between disease groups indicated that increased Lp(a) conferred a similar risk for all groups studied.
Conclusions:
Lp(a) constitutes a stable risk factor of similar magnitude for 4 major forms of vascular disease. This association was not altered by exposure to standard lipid-lowering therapy.
Related Concept Videos
Atherosclerosis I: Introduction
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Lipid-derived Compounds in the Human Body
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin, delayed...
Peripheral Artery Disease I: Introduction
Atherosclerosis III: Management
Cholesterol: Significance and Regulation
Considering cholesterol and...